Literature DB >> 22986797

Co-occurring psychotic and addictive disorders: neurobiology and diagnosis.

Stephen Ross1, Eric Peselow.   

Abstract

Psychosis and substance abuse are intimately related. Psychotic spectrum illnesses commonly co-occur with substance use disorders (SUDs), and many substances of abuse can cause or exacerbate psychotic symptoms along a temporal spectrum from acute to chronic presentations. Despite the common co-occurrence between psychotic spectrum illnesses and SUDs, they are often under-recognized and undertreated, leading to poor treatment outcomes. Accurate detection and diagnosis of individuals with psychotic illness co-occurring with addictive disorders is key to properly treat such disorders. This article will review the nature of the relationship between psychosis and substance abuse by examining prevalence rates of each disorder alone and their rates of co-occurrence, the neurobiological basis for substance abuse comorbidity in schizophrenia spectrum disorders, key and salient aspects related to accurate diagnosis along a continuum from acute to subacute to chronic conditions, and pitfalls associated with diagnostic dilemmas. A case example will be used to highlight key points related to diagnostic challenges.

Entities:  

Mesh:

Year:  2012        PMID: 22986797     DOI: 10.1097/WNF.0b013e318261e193

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  30 in total

1.  Sexual Orientation, Adverse Childhood Experiences, and Comorbid DSM-5 Substance Use and Mental Health Disorders.

Authors:  Sean Esteban McCabe; Tonda L Hughes; Brady T West; Rebecca J Evans-Polce; Phil T Veliz; Kara Dickinson; Vita V McCabe; Carol J Boyd
Journal:  J Clin Psychiatry       Date:  2020-12-01       Impact factor: 4.384

Review 2.  TAAR1 and Psychostimulant Addiction.

Authors:  Jianfeng Liu; Ruyan Wu; Jun-Xu Li
Journal:  Cell Mol Neurobiol       Date:  2020-01-23       Impact factor: 5.046

Review 3.  [Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].

Authors:  Anton Schmick; Josef Jenewein; Sönke Böttger
Journal:  Neuropsychiatr       Date:  2018-01-11

4.  Psychiatric and substance use disorders in a predominately low-income, black sample in early midlife.

Authors:  Christina F Mondi; Alison Giovanelli; Suh-Ruu Ou; Arthur J Reynolds
Journal:  J Psychiatr Res       Date:  2022-02-16       Impact factor: 4.791

5.  Psychiatric disorders and associated risk factors in a sample of adolescents in Gaborone, Botswana: a cross-sectional study.

Authors:  Anthony A Olashore; Wendy Brooks; Hlanganiso Roy; Fatai Adewole Adebayo; Bonginkosi Chiliza
Journal:  BMC Pediatr       Date:  2022-06-29       Impact factor: 2.567

6.  CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Authors:  T N Douma; M J Millan; D Boulay; G Griebel; P M Verdouw; K G Westphal; B Olivier; L Groenink
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

Review 7.  Overlapping evidence of innate immune dysfunction in psychotic and affective disorders.

Authors:  H K Hughes; P Ashwood
Journal:  Brain Behav Immun Health       Date:  2020-01-26

8.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

9.  Structural brain characteristics of anabolic-androgenic steroid dependence in men.

Authors:  Lisa E Hauger; Lars T Westlye; Anders M Fjell; Kristine B Walhovd; Astrid Bjørnebekk
Journal:  Addiction       Date:  2019-05-15       Impact factor: 6.526

Review 10.  Resilience in Adult Health Science Revisited-A Narrative Review Synthesis of Process-Oriented Approaches.

Authors:  Nina Hiebel; Milena Rabe; Katja Maus; Frank Peusquens; Lukas Radbruch; Franziska Geiser
Journal:  Front Psychol       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.